Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations

Medical Mycology

Volumn 52, Issue 2, 2014, Pages 140-148

  Nyilasi, Ildikó ^a,b   Kocsubé, Sándor ^a,b   Krizsán, Krisztina ^a   Galgóczy, László ^a   Papp, Tamás ^a   Pesti, Miklós ^c   Nagy, Katalin ^d   Vágvölgyi, Csaba ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PannonPharma Ltd   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

antifungal susceptibility testing; dermatophytes; drug combination; Statin; synergism

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ATORVASTATIN; FLUCONAZOLE; FLUINDOSTATIN; GRISEOFULVIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NYSTATIN; PRAVASTATIN; PRIMYCIN; ROSUVASTATIN; SIMVASTATIN; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTHRODERMA GYPSEUM; ARTICLE; BROTH DILUTION; CONCENTRATION RESPONSE; DERMATOPHYTE; DRUG POTENTIATION; FUNGAL STRAIN; IN VITRO STUDY; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; ARTHRODERMATACEAE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROSPORUM; TRICHOPHYTON;

ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; DRUG SYNERGISM; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MICROSPORUM; TRICHOPHYTON;

EID: 84942086652     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2013.828160     Document Type: Article

References (43)

1. Afeltra J, Verweij PE. Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol Infect Dis 2003; 22: 397-407
2. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118
3. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect Dis 2007; 7: 358-368
4. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: A systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61: 774-785
5. Galg ́ oczy L, Nyilasi I, Papp T, Vágv ? olgyi C. Are statins applicable for prevention and treatment of zygomycosis?Clin Infect Dis 2009; 49: 483-484
6. Sun H-Y, Singh N. Antimicrobial and immunomodulatory attributes of statins: Relevance in solid-organ transplant recipients. Clin Infect Dis 2009; 48: 745-755
7. Roze LV, Linz JE. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 1998; 25: 119-133
8. Lukács G, Papp T, Nyilasi I, Nagy E, Vágv ? olgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004; 42: 5400-5402
9. Gyetvai Á, Emri T, Taká cs K, et al. Lovastatin possesses a fungistatic effect against Candida albicans but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 2006; 6: 1140-1148
10. Macreadie IG, Johnson G, Schlosser T,Macreadie PI.Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006; 262: 9-13
11. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50: 96-103
12. Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41: 850-852
13. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 2002; 51: 105-109
14. Galg ́ oczy L, Papp T, Lukács G, et al. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 2007; 270: 109-115
15. Natesan SK, Chandrasekar PH, Alangaden GJ, Manavathu EK. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 2008; 60: 369-373
16. Nyilasi I, Kocsub́e S, Pesti M, et al. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol 2010a; 59: 200-205
17. Nyilasi I, Kocsub́e S, Krizs án K, et al. In vitro synergistic interactions between various statins and azoles in their effects against some clinically important fungi. FEMS Microbiol Lett 2010b; 307: 175-184
18. Nyilasi I, Kocsub́e S, Galǵ oczy L, et al. Effect of different statins on the antifungal activity of polyene antimycotics. Acta Biol Szeged 2010c; 54: 33-36
19. Galg ́ oczy L, Lukács G, Nyilasi I, Papp T, Vágv ? olgyi C. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. Acta Biol Hung 2010; 61: 356-365
20. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-259
21. Walsh TJ, Groll AH. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999; 1: 247-261
22. Fernández-Torres B, Cabanes FJ, Carrillo-Munoz AJ, et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002; 40: 3999-4003
23. Niewerth M, Korting HC. The use of systemic antimycotics in dermatotherapy. Eur J Dermatol 2000; 10: 155-160
24. Millikan LE. Current concepts in systemic and topical therapy for superficial mycoses. Clin Dermatol 2010; 28: 212-216
25. Lorenz RT, Parks LW. Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 1990; 34: 1660-1665
26. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved standard, 2nd ed. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2008
27. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard, 3rd ed. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008
28. Santos DA, Barros MES, Hamdan JS. Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J Clin Microbiol 2006; 44: 98-101
29. Gisi U. Synergistic interaction of fungicides in mixtures. Phytopathology 1996; 86: 1273-1279
30. American Society for Microbiology. Instructions to authors. Antimicrob Agents Chemother 2013 Jan; 57: Available from: .
31. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715
32. Tashiro M, Kimura S, Tateda K, et al. Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. Med Mycol 2012; 50: 353-360
33. Norris HA, Elewski BE, Ghannoum MA. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. J Am Acad Dermatol 1999; 40(Suppl. 6): S9-13
34. Galg ́ oczy L, Nyilasi I, Papp T, Vágv ? olgyi C. Statins as antifungal agents. World J Clin Infect Dis 2011; 1: 4-10
35. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanism of statin-mediated inhibition of small G-protein function. J Biol Chem 2005; 280: 34202-34209
36. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic strategies: Ischemic stroke and dementia. J Atheroscler Thromb 2004; 11: 253-264
37. Kivist ö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53
38. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005; 19: 117-125
39. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166: 353-367
40. Herman RJ. Drug interactions and the statins. CMAJ 1999; 161: 1281-1286
41. Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68: 391-400
42. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-416
43. Triscari J, O'Donnell D, Zinny M, Pan HY. Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995; 35: 142-144.